BR9814904A - Polinucleotìdeo isolado que codifica um polipeptìdeo, polipeptìdeo isolado, e, anticorpo. - Google Patents

Polinucleotìdeo isolado que codifica um polipeptìdeo, polipeptìdeo isolado, e, anticorpo.

Info

Publication number
BR9814904A
BR9814904A BR9814904-0A BR9814904A BR9814904A BR 9814904 A BR9814904 A BR 9814904A BR 9814904 A BR9814904 A BR 9814904A BR 9814904 A BR9814904 A BR 9814904A
Authority
BR
Brazil
Prior art keywords
polypeptide
isolated
antibody
polynucleotide encoding
antibodies
Prior art date
Application number
BR9814904-0A
Other languages
English (en)
Inventor
Darrel C Conklin
Betty A Haldeman
Angelica Grossmann
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of BR9814904A publication Critical patent/BR9814904A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Animal Husbandry (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)

Abstract

"POLINUCLEOTìDEO ISOLADO QUE CODIFICA UM POLIPETìDEO, POLIPEPTìDEO ISOLADO, E, ANTICORPO". Um polipeptídeo mamífero semelhante à citosina, denominado Zcyto10, polinucleotídeos codificando o mesmo, anticorpos que se ligam especificamente ao polipeptídeo, e anticorpos anti-idiotípicos que se ligam aos anticorpos. O Zcyto10 é útil para promover a cura de feridas e para estimular a proliferação de plaquetas.
BR9814904-0A 1997-11-26 1998-11-25 Polinucleotìdeo isolado que codifica um polipeptìdeo, polipeptìdeo isolado, e, anticorpo. BR9814904A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97915697A 1997-11-26 1997-11-26
PCT/US1998/025228 WO1999027103A1 (en) 1997-11-26 1998-11-25 Mammalian cytokine-like polypeptide-10

Publications (1)

Publication Number Publication Date
BR9814904A true BR9814904A (pt) 2000-10-03

Family

ID=25526742

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814904-0A BR9814904A (pt) 1997-11-26 1998-11-25 Polinucleotìdeo isolado que codifica um polipeptìdeo, polipeptìdeo isolado, e, anticorpo.

Country Status (20)

Country Link
EP (3) EP1719780A3 (pt)
JP (2) JP5191619B2 (pt)
KR (1) KR100574387B1 (pt)
CN (2) CN1247780C (pt)
AT (1) ATE269902T1 (pt)
AU (1) AU739420B2 (pt)
BR (1) BR9814904A (pt)
CA (1) CA2312000C (pt)
CZ (1) CZ300849B6 (pt)
DE (1) DE69824755T2 (pt)
DK (1) DK1032671T3 (pt)
EA (2) EA010741B1 (pt)
ES (1) ES2218872T3 (pt)
HU (1) HU227703B1 (pt)
IL (2) IL136076A0 (pt)
NO (2) NO326561B1 (pt)
NZ (1) NZ504751A (pt)
PL (2) PL195304B1 (pt)
UA (2) UA73275C2 (pt)
WO (1) WO1999027103A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
DK1616575T3 (da) 1999-12-23 2012-09-10 Zymogenetics Inc Fremgangsmåde til behandling af inflammation
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
ATE485306T1 (de) 1999-12-23 2010-11-15 Zymogenetics Inc Löslicher interleukin-20-rezeptor
ATE547525T1 (de) 2000-08-08 2012-03-15 Zymogenetics Inc Lösliche zcyctor 11 cytokinrezeptoren
ES2267814T3 (es) 2000-09-15 2007-03-16 Zymogenetics, Inc. Metodo para tratar la inflamacion.
WO2002034917A2 (en) * 2000-10-20 2002-05-02 Zymogenetics, Inc. Secreted alpha-helical cytokine-like protein zlmda24
EP1390060A2 (en) * 2001-01-26 2004-02-25 Eli Lilly And Company Use of lp82 to treat body weight disorders
MXPA03007653A (es) * 2001-02-28 2003-12-04 Lilly Co Eli Uso de lp82 para tratar trastornos hematopoyeticos.
EP1439850A4 (en) * 2001-10-22 2006-05-03 Lilly Co Eli SOLUBLE PROTEINS THAT RESIST CYTOKIN SIGNAL TRANSFER PATHS
PT1531843E (pt) 2001-12-17 2011-10-27 Zymogenetics Inc Método para tratar o cancro cervical
EP1606316A2 (en) 2003-03-24 2005-12-21 ZymoGenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
EP2087905A2 (en) 2003-08-08 2009-08-12 Novo Nordisk A/S Interleukin-20 for treating and diagnosing conditions associated with neovascularisation
WO2005052001A2 (en) * 2003-11-21 2005-06-09 Zymogenetics, Inc. Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
MXPA06006747A (es) 2003-12-19 2006-08-18 Novo Nordisk As Procesamiento de peptidos y proteinas.
RU2385879C2 (ru) 2004-01-21 2010-04-10 Ново Нордиск Хелс Кеа Аг Способ конъюгации пептидов, опосредованной трансглутаминазой
CA2558811A1 (en) 2004-03-08 2005-09-22 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
WO2006047249A1 (en) 2004-10-22 2006-05-04 Zymogenetics, Inc. Anti-il-22ra antibodies and binding partners and methods of using in inflammation
WO2006086396A2 (en) 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
CN102084004B (zh) 2008-05-27 2016-01-20 丹麦达科有限公司 杂交组合物和方法
EP2297203A1 (en) 2008-06-30 2011-03-23 Novo Nordisk A/S Anti-human interleukin-20 antibodies
CN102281898B (zh) * 2008-10-07 2015-06-03 成功大学 Il-20拮抗剂在治疗类风湿性关节炎和骨质疏松症中的应用
WO2010097656A1 (en) 2009-02-26 2010-09-02 Dako Denmark A/S Compositions and methods for performing a stringent wash step in hybridization applications
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
EP2761028A1 (en) 2011-09-30 2014-08-06 Dako Denmark A/S Hybridization compositions and methods using formamide
EP3252173A1 (en) 2011-10-21 2017-12-06 Dako Denmark A/S Hybridization compositions and methods
ES2669244T3 (es) * 2012-03-05 2018-05-24 Seegene, Inc. Detección de variación de nucleótidos en una secuencia de ácido nucleico diana mediante escisión CTO y ensayo de extensión
WO2013164440A1 (en) 2012-05-03 2013-11-07 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
WO2017202813A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
CN113248567B (zh) * 2021-02-10 2023-02-03 渤海大学 一种苦味受体阻滞肽及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065396A1 (en) * 1996-08-30 2009-06-03 Human Genome Sciences, Inc. Interleukin-19
DK1616575T3 (da) * 1999-12-23 2012-09-10 Zymogenetics Inc Fremgangsmåde til behandling af inflammation

Also Published As

Publication number Publication date
UA86350C2 (en) 2009-04-27
CN1247780C (zh) 2006-03-29
CA2312000A1 (en) 1999-06-03
DK1032671T3 (da) 2004-10-11
HUP0100436A2 (hu) 2001-06-28
ATE269902T1 (de) 2004-07-15
NO20002698L (no) 2000-07-20
WO1999027103A1 (en) 1999-06-03
CZ20001910A3 (cs) 2000-11-15
HU227703B1 (en) 2011-12-28
ES2218872T3 (es) 2004-11-16
KR20010032490A (ko) 2001-04-25
EP1719780A2 (en) 2006-11-08
NO20074516L (no) 2000-07-20
JP5191619B2 (ja) 2013-05-08
NZ504751A (en) 2001-10-26
IL136076A0 (en) 2001-05-20
PL340755A1 (en) 2001-02-26
EA010741B1 (ru) 2008-10-30
EA005581B1 (ru) 2005-04-28
DE69824755D1 (de) 2004-07-29
AU739420B2 (en) 2001-10-11
NO20002698D0 (no) 2000-05-26
JP2001524313A (ja) 2001-12-04
NO329731B1 (no) 2010-12-13
EA200000565A1 (ru) 2000-12-25
DE69824755T2 (de) 2005-08-04
EP1424393A3 (en) 2004-06-09
JP2010187698A (ja) 2010-09-02
EP1424393A2 (en) 2004-06-02
JP5331054B2 (ja) 2013-10-30
NO326561B1 (no) 2009-01-12
CN1282372A (zh) 2001-01-31
EA200401501A1 (ru) 2006-02-24
CN1618969A (zh) 2005-05-25
EP1032671A1 (en) 2000-09-06
HUP0100436A3 (en) 2003-08-28
EP1719780A3 (en) 2006-12-20
IL136076A (en) 2007-12-03
CA2312000C (en) 2013-03-26
UA73275C2 (en) 2005-07-15
CZ300849B6 (cs) 2009-08-26
PL198687B1 (pl) 2008-07-31
KR100574387B1 (ko) 2006-04-27
EP1032671B1 (en) 2004-06-23
AU1607799A (en) 1999-06-15
PL195304B1 (pl) 2007-08-31

Similar Documents

Publication Publication Date Title
BR9814904A (pt) Polinucleotìdeo isolado que codifica um polipeptìdeo, polipeptìdeo isolado, e, anticorpo.
PT94565A (pt) Novos anticorpos reactivos com carcinomas humanos
DE68914929D1 (de) Emulgierte Zusammensetzung.
DE69000210D1 (de) Herstellung von olefinen.
DE68909037D1 (de) Belüftung von Flüssigkeiten.
DE69515938T2 (de) Reibbelagmaterialien
DK412489A (da) Alfa-underenheden af mac-1-leukocytadhaesionsreceptoren
DE68909432D1 (de) Direkte fixierung von geflochtenen strukturen.
DE3668200D1 (de) Pumpbares aufschuettungsmaterial mit hoher festigkeit.
BR9006389A (pt) Cimento asfaltico modificado
BR8905709A (pt) Composicoes de cimento tixotropicas
DE68901414D1 (de) Kohlenwasserstoff-dehydrierungsreakionen.
TR199600931A2 (tr) Insaat malzemesi karisimi.
DE69104829D1 (de) Herstellung von reibbelägen.
DE68919463D1 (de) Bremsbackenführungselement und dieses verwendende Bremse.
DE3750606D1 (de) Gipsentschwefelung.
BR8900543A (pt) Composicao para o beneficiamento de fibras sinteticas,processo para sua preparacao e aplicacao
BR8701478A (pt) Mistura de aclaradores oticos,aplicacao e agente para o aclaramento otico de fibras
DE3766908D1 (de) Reibungsmaterial.
DE69408974T2 (de) Verstärkung von chemilumineszenzreaktionen
BR9007071A (pt) Anticorpos de anti-idiotipos que reagem com idiotopos divididos,expressos por linfomas humanos e auto-anticorpo
NO902162D0 (no) Fremstilling av bituminoes betong omfattende traadstykker.
DE3869884D1 (de) Polysiloxanmodifizierter zement.
DE3577400D1 (de) Hartelastische, chirurgische nahtmaterialien.
DK424789A (da) Instant mousseblanding

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO DO PRESENTE PEDIDO, UMA VEZ QUE NAO APRESENTA SUFICIENCIA DESCRITIVA (ART. 24 DA LPI); AS REIVINDICACOES ESTAO INDEFINIDAS E/OU NAO ESTAO FUNDAMENTADAS NO RELATORIO DESCRITIVO (ART. 25 DA LPI).

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 13A, 14A E 15A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2256 DE 01/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ATE A 22A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.